

San Antonio Breast Cancer Symposium 2025

Abstracts équipes Oncopole

- PS2-07-23 - Predictive markers of distant recurrence from randomized chemotherapy regimens for hormone receptor-positive breast cancer patient in the PACS-01 trial.**
Frédérique Penault-Llorca¹, Amelie Lusque², Thomas Filleron², Kevin Tran³, Lili Du³, Rick Baehner^{4,5}, Florence Dalenc⁶, Magali Lacroix-Triki⁷, Thomas Bachelot⁸, Fabrice Andre⁹, Pascal Boucher¹⁰, Jérôme Lemonnier¹⁰, W. Fraser Symmans³.
- PS1-10-21 - Switching CDK4/6 inhibitors due to Toxicity in first-line treatment of HR+/HER2-metastatic breast cancer: Incidence and Outcomes from the ESME Cohort.**
Thomas PAPAZYAN, Amelie LUSQUE, Audrey MAILLIEZ, Thomas BACHELOT, Thomas GRINDA, Anthony GONCALVES, Etienne BRAIN, Aude-Marie SAVOYE, Monica ARNELOS, Christelle LEVY, Isabelle DESMOULINS, Thibault DE LA MOTTE ROUGE, Thierry PETIT, Caroline BAILLEUX, Marie-Ange MOURET-REYNIER, Vincent MASSARD, Marianne LEHEURTEUR, Lise BOSQUET, William JACOT, Mario CAMPONE, Jean-Sebastien FRENEL
- PS1-11-29 - Factors predicting the effectiveness of CDK4/6 inhibitor rechallenge following progression on first-line endocrine therapy combined with a CDK4/6 inhibitor in ER+ metastatic breast cancer in the French ESME Database.**
Papazyan Thomas, Lusque Amelie, Mailliez Audrey, Bachelot Thomas, Suzette Delaloge, Goncalves Anthony, Brain Etienne, Savoye Aude-Marie, Arnedos Monica, Levy Christelle, Desmoulins Isabelle, De La Motte Rouge Thibault, Carole Pflumio, Mouret-Reynier Marie-Ange, Massard Vincent, Leheurteur Marianne, Bosquet Lise, Jacot William, Campone Mario, Frenel Jean-Sebastien.
- PS2-04-25 - Efficacy of maintenance endocrine therapy combined with trastuzumab + pertuzumab following taxane induction in HR+/HER2+ metastatic breast cancer: A real-world reproduction of the PATINA trial control arm.**
Laurent Mathiot, Amélie Lusque, Thomas Grinda, Thierry Petit, Audrey Mailliez, Thomas Bachelot, Monica Arnedos, Christelle Levy, Etienne Brain, Vincent Massard, Thibault de la Motte Rouge, Anthony Goncalves, Isabelle Desmoulins, Marie-Ange Mouret-Reynier, Aude-Marie Savoye, Marianne Leheurteur, Lise Bosquet, Florence Dalenc, William Jacot, Jean-Sébastien Frenel
- PS2-04-29 - PARP inhibitors use in patients in germline *PALB2* or somatic *BRCA1/2* mutations carriers with metastatic breast cancer: Real life data from the ESME database**
Pauline ROTTIER¹, Léonor CHALTIEL², Zoé NEVIERE¹, William JACOT³, Véronique DIERAS⁴, Audrey MAILLIEZ⁵, Florence DALENC², Thomas BACHELOT⁶, Monica ARNELOS⁷, Jean-Sébastien FRENEL⁸, Etienne BRAIN⁹, Vincent MASSARD¹⁰, Anthony GONCALVES¹¹, Isabelle DESMOULINS¹², Baptiste SAUTEREY¹³, Suzette DELALOGUE¹⁴, Carole PFLUMIO¹⁵, Lise BOSQUET¹⁶, Georges EMILE¹
- PD3-08 - Evidence Accumulates Against Sequencing Topo1-ADCs in HER2-Low Metastatic Breast Cancers: results from International, retrospective, real-world ADC-Low-Europe cohort.**
F. Poumeaud, M. Morisseau, B. Verret, S. Ladoire, S. Cavaillon, M. Reich, A. Patsouris, S. Bécourt, R. Vion, M. Brunet, C. Lévy, L. Drouin, H. Bischoff, Z. Khalil, F. Vaz, R. Sobral, A. Deleuze, E. Deluche, T. Grellety, T. Reverdy, M. Pagliuca, E. Volant, C. Rivier, F. Fiteni, A. de Nonneville, F. Dalenc.
- PS2-04-30 - Enrolment of Patients with Metastatic Lobular Breast Cancer in Clinical Trials in the Multicenter ESME Cohort.**

- E. De Maio D'Esposito, L. Chaltiel, V. Massard, A. Mailliez, T. Grinda, J-S. Frenel, E. Brain, T. Bachelot, A. Gonçalves, B. Sauterey, D. Pasquier, T. Petit, L. Bosquet, S. Guiu, F. Dalenc
8. **PS1-10-15 - Impact of modern imaging on survival in a retrospective and consecutive cohort of 145 HR+/HER2 negative oligometastatic breast cancer.**
Jean-Louis Lacaze, Bastien Cabarrou, Ciprian Chira, Thibaut Cassou-Mounat, Florence Dalenc, Celine Dalmasso, Eleonora De Maio, Eva Jouve, Clément Korenbaum, Carole Massabeau, Vincent Nicolai, Gabrielle Selmes, Mony Ung
 9. **PS1-12-28. Real-world outcomes of first line palbociclib combined with endocrine treatment in HR+/HER2- metastatic breast cancer: 5-year data from the French ESME cohort**
T. Grinda¹, S. Eltaief², E. Brain³, T. Bachelot⁴, V. Diéras⁵, F. Dalenc⁶, V. Massard⁷, M. Decrop⁸, A. Coumert⁸, M. Arnedos⁹, A. Mailliez¹⁰, M. Carton¹¹, L. Bosquet¹², J. Frenel¹³, W. Jacot¹⁴;
 10. **PS1-13-24. Safety analysis of ASCENT-03, a phase 3 study of sacituzumab govitecan (SG) vs chemotherapy (chemo) for previously untreated advanced triple-negative breast cancer (TNBC) in patients (pts) who are not candidates for PD-(L)1 inhibitors (PD-[L]1i)**
S. Hurvitz¹, A. Bardia², S. M. Tolaney³, K. Punie⁴, C. Barrios⁵, A. Schneeweiss⁶, R. Hegg⁷, E. Tokunaga⁸, J. Sohn⁹, S. Kim¹⁰, S. Im¹¹, Y. Park⁸, B. Rapoport¹², D. Motola¹³, D. A. Yardley¹⁴, F. Dalenc¹⁵, M. Oliveira¹⁶, B. Pistilli¹⁷, G. Vidal¹⁸, S. Paluch-Shimon¹⁹, B. Xu²⁰, T. Valdez²¹, D. Zhang²¹, S. Padman²¹, J. Cortés²²;
 11. **PS2-02-09. Fr-pop: Real-world data from 7,687 high-risk TNBC patients treated with perioperative pembrolizumab in France**
A. de Nonneville¹, D. Loirat², J. Ribeiro³, S. Becourt⁴, M. Benderra⁵, N. Benard⁶, M. Campone⁷, F. Dalenc⁸, O. Derbel⁹, I. Desmoulins¹⁰, A. Deleuze¹¹, G. Emile¹², A. Goncalves¹, J. Grenier¹³, W. Jacot¹⁴, C. Liautard⁶, L. Mansi¹⁵, M. A. Mouret Reynier¹⁶, C. Perkins⁶, B. Pistilli³, J. P. Spano¹⁷, A. Vasseur¹⁸, F. Penault Llorca¹⁹, O. Tredan²⁰;
 12. **RF7-03. Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestran (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC)**
F. Bidard¹, E. L. Mayer², Y. Park³, W. Janni⁴, C. Ma⁵, M. Cristofanilli⁶, G. Bianchini⁷, K. Kalinsky⁸, H. Iwata⁹, S. Chia¹⁰, A. Brufsky¹¹, P. Fasching¹², Z. Nowecki¹³, J. Pascual¹⁴, E. Gal-Yam¹⁵, W. Chung¹⁶, S. Im¹⁷, A. Zambelli¹⁸, F. Dalenc¹⁹, M. Oliveira²⁰, S. Fox²¹, M. Selvi Miralles²¹, C. Morrow²², C. Huang Bartlett²³, N. C. Turner²⁴;
 13. **RF7-05. Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPitello-291 trial**
N. C. Turner¹, M. Oliveira², S. J. Howell³, F. Dalenc⁴, W.-P. Chung⁵, J. Cortés⁶, H. L. Gomez Moreno⁷, X. Hu⁸, K. Jhaveri⁹, P. Krivorotko¹⁰, G. Lerzo¹¹, S. Loibl¹², S. Morales Murillo¹³, Z. Nowecki¹⁴, M. Okera¹⁵, Y. Park¹⁶, J. Sohn¹⁷, M. Toi¹⁸, L. Zhukova¹⁹, E. DeBruin²⁰, A. Nardone²¹, A. Spencer²⁰, M. Fulford²², G. Schiavon²⁰, H. S. Rugo²³;
 14. **PS5-01-22. Efficacy of second- or third-line Tucatinib, Trastuzumab, and Capecitabine (TTC) following trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer: A multicenter French cohort study.**
J. S. Frenel¹, A. de Nonneville², C. Guerin-Charbonnel³, J. Zeghondy⁴, L. Mathiot¹, A. Mailliez⁵, F. Poumeaud⁶, N. Isambert⁷, M. Arnedos⁸, F. Le Du⁹, L. Galland¹⁰, R. Kabirian¹¹, S. Guiu¹², L. Poestch¹³, E. Deluche¹⁴, F. Cherifi¹⁵, F. Dalenc⁶, E. Volant¹, B. Pistilli⁴, T. San¹⁶, T. Bachelot¹⁷, A. Patsouris¹⁸, F. Bocquet¹⁹, L. Larrouquere¹⁷, D. Loirat²⁰;
 15. **PS5-07-12. Opt-pembro: a phase III randomized trial of adjuvant pembrolizumab omission in patients with early-stage triple-negative breast cancer achieving pathologic complete response after neoadjuvant chemo-immunotherapy**
J. M. Ribeiro¹, F. Duhoux², E. Romano³, B. Verret¹, F. Dalenc⁴, E. Azambuja⁵, S. Ladoire⁶, A. Rorive⁷, A. Mailliez⁸, P. Bénédicte⁹, C. Lefeuvre¹⁰, D. Taylor¹¹, A. Gonçalves¹², K.

Punie¹³, M. Mouret-Reynier¹⁴, C. Fontaine¹⁵, C. Bailleux¹⁶, E. Naert¹⁷, P. Corbaux¹⁸, F. Derouane¹⁹, M. Leheuteur²⁰, E. Jacquet²¹, M. Robert²², A. Lemoine²³, T. Robinson²⁴, R. Salgado²⁵, M. Van Bockstaele²⁶, M. Lambertini²⁷, S. Tillaux²⁸, T. Sara²⁹, A. Partridge²⁹, L. Carrey³⁰, K. Pilger³¹, J. Lemonier³², S. Mardinian³³, S. Mijonnet³³, F. Clement-Bidard³⁴, T. Bachelot³⁵, V. Ines³⁶, S. Michiels²⁸, T. Olivier³⁵;

- 16. PS5-07-16. Cappa, a phase 2 study to evaluate capecitabine plus pembrolizumab as post-operative adjuvant therapy for triple-negative breast cancer with residual disease after neoadjuvant chemo-immunotherapy**

D. Loirat¹, F. C. Bidard¹, J. Grenier², T. L'Haridon³, A. Kieffer⁴, F. Dalenc⁵, C. Goislard De Monsabert⁶, F. Ricci⁷, M. By⁸, D. Bello Roufai¹, Y. Kirova⁹, T. Roque¹⁰, A. Savignoni¹¹, J. Y. Pierga¹;

- 17. PS5-09-23. A Phase 2 study of zelenectide pevedotin, a Bicycle Drug Conjugate, in patients with NECTIN4 amplified advanced breast cancer (Duravelo-3)**

P. A. Kaufman¹, P. Aftimos², J. Cortes³, G. Curigliano⁴, F. Dalenc⁵, M. Danso⁶, K. Jhaveri⁷, M. Rimawi⁸, C. Saura⁹, P. Savas¹⁰, P. Schmid¹¹, J. Ricker¹², K. Josephs¹², C. Xu¹³, E. Hamilton¹⁴;